In summary, clinical studies have consistently demonstrated that low-dose IL-2 therapy in SLE is well tolerated, and capable of increasing suppressive Treg population that appears to provide complementary immunomodulatory effects on the treatment of SLE. Here, IL2 is linked to systemic lupus erythematosus.